司美格鲁肽皮下注射致肌肉18F-FDG摄取增高并降低PET/CT图像质量:一例病例报告
本病例报告描述一名48岁男性糖尿病患者,同日皮下注射司美格鲁肽后进行PET/CT,出现肌肉弥漫性18F-FDG摄取增高,掩盖潜在病灶。停用司美格鲁肽6天后复查,肌肉活性恢复正常,多发病灶清晰显示。作者建议糖尿病患者PET/CT前至少停用司美格鲁肽24小时。
要点
- 同日皮下注射司美格鲁肽可致肌肉弥漫性18F-FDG摄取增高,掩盖病灶。
- 停用司美格鲁肽6天后肌肉摄取恢复正常,病灶清晰可见。
- 建议糖尿病患者PET/CT前至少停用司美格鲁肽24小时。
核心结论
- 同日皮下注射司美格鲁肽可显著增加肌肉18F-FDG摄取,降低PET/CT图像质量,影响病灶检出。
研究设计与样本
- 病例报告:一名48岁男性糖尿病患者,先后三次PET/CT扫描对比。
主要发现
- 基线PET/CT(未近期使用司美格鲁肽)显示鼻咽部和淋巴结局灶性摄取,无肌肉干扰。
- 停用司美格鲁肽6天后第三次扫描显示肌肉活性正常化,多个高代谢病灶清晰可见。
关键数值与推荐
- 建议糖尿病患者在PET/CT前至少停用司美格鲁肽24小时以确保诊断准确性。
临床怎么用
- 对使用司美格鲁肽的糖尿病患者,安排PET/CT时应询问用药时间,必要时停药至少24小时。
局限性
- single case report, causality cannot be established, generalizability limited.
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist widely used in diabetes management, has not been previously reported to interfere with PET/CT imaging. This case highlights a novel observation regarding same-day subcutaneous semaglutide injection leading to increased muscular 18F-FDG uptake, which compromises lesion detectability. CASE PRESENTATION: A 48-year-old male with diabetes presented with "right ear fluid outflow" and underwent a baseline PET/CT scan without recent semaglutide, showing focal uptake in the nasopharynx and lymph nodes without muscular interference. Thirteen months later, he returned with lower back pain. A repeat PET/CT performed on the same day as semaglutide injection showed diffusely elevated muscle uptake, obscuring potential lesions. After discontinuing semaglutide for 6 days, a third scan revealed normalized muscular activity and clear visualization of multiple hypermetabolic lesions. CONCLUSIONS: This is the first report indicating that same-day semaglutide administration can significantly reduce PET/CT image quality by increasing muscle FDG uptake. Clinicians should consider discontinuing semaglutide at least 24 h prior to PET/CT in diabetic patients to ensure diagnostic accuracy.
引用
- Hong DC, Le L, Chen W, et al. Subcutaneous injection of semaglutide causes increased muscle uptake of 18F-FDG and reduces the imaging quality of PET/CT: a case report. EJNMMI Res. 2026. PMID: 42118195. doi:10.1186/s13550-026-01373-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。